Overview

Cefixime for Alternative Syphilis Treatment

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to evaluate the efficacy of oral cefixime as an alternative treatment for syphilis infection. One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema Pallidum Particle Agglutination assay and RPR titer ≥ 1/8) will be recruited. Participants will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime. During the study, participants will visit the clinic up to 5 times; at baseline visit, at 3, 6, 12 months after treatment initiation. Participants of the cefixime group will be required to visit the clinic 14 days after treatment initiation. In each visit, participants will be asked about current symptoms and do laboratory tests for syphilis (RPR). Subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a positive treatment response.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Los Angeles
Collaborator:
AIDS Healthcare Foundation
Treatments:
Cefixime
Penicillin G
Penicillin G Benzathine
Penicillin G Procaine
Penicillins